Unnatural Products, adding a macrocyclic peptide discovery platform to complement its antibody engineering. argenx signed a ...

Single-partner platforms can unify manufacturers, prescribers, and patients to eliminate gaps, cut costs, and boost treatment ...

Ignite Proteomics measures phosphorylation states to show which proteins are actively driving a tumor—guiding therapy beyond ...

Unnatural Products for up to $1.15 billion to expand its immunology capabilities, GiftHealth’s Chip Parkinson on how single-partner platforms can transform the prescription journey, and Partha Anbil ...

Hims & Hers partners with Eli Lilly to sell Zepbound and Foundayo directly on its platform, Novo Nordisk terminates its ...

How microgravity is opening new possibilities for drug R&D and manufacturing, a pharma funding roundup covers Boehringer ...

As Medicare negotiation, PBM reform, and cash-pay channels converge, winning on auditable net value matters more than cutting ...

The agreement provides access for prescribed patients to Lilly's obesity medicines self-pay pricing starting at $149 per ...

When tumors shift, old treatments stop working. Dr. Brian Corgiat explains why real-time tumor profiling is critical to ...

Ignite Proteomics’ Dr. Brian Corgiat explains why tumors change over time—and why treatment must adapt to the current tumor, ...

ANI Pharmaceuticals makes an offer to acquire Egetis Therapeutics, as Egetis separately agrees to sell its priority review ...

ANI Pharmaceuticals makes an offer to acquire Egetis Therapeutics as Egetis separately sells its priority review voucher for ...